fluconazole has been researched along with Ventilator-Associated Pneumonia in 2 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Manzoni, P | 1 |
De Luca, D | 1 |
Stronati, M | 1 |
Jacqz-Aigrain, E | 1 |
Ruffinazzi, G | 1 |
Luparia, M | 1 |
Tavella, E | 1 |
Boano, E | 1 |
Castagnola, E | 1 |
Mostert, M | 1 |
Farina, D | 1 |
Nseir, S | 1 |
Jozefowicz, E | 1 |
Cavestri, B | 1 |
Sendid, B | 1 |
Di Pompeo, C | 1 |
Dewavrin, F | 1 |
Favory, R | 1 |
Roussel-Delvallez, M | 1 |
Durocher, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study[NCT00934934] | Phase 2 | 61 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to slow enrollment) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure (NCT00934934)
Timeframe: post randomization
Intervention | score on a scale (Mean) |
---|---|
Placebo | 5.9 |
Antifungal | 5.9 |
Number of days free of antibiotic use within the first 28 days (NCT00934934)
Timeframe: 28 days
Intervention | days (Median) |
---|---|
Placebo | 16 |
Antifungal | 10 |
(NCT00934934)
Timeframe: 28 days
Intervention | pg/ml (Mean) |
---|---|
VAP withCandida | 116 |
VAP Without Candida | 129.1 |
(NCT00934934)
Timeframe: 28 days
Intervention | mg/l (Mean) |
---|---|
VAP withCandida | 133 |
VAP Without Candida | 145.7 |
Measure of the duration of participant stay in the ICU (NCT00934934)
Timeframe: 28 days
Intervention | days (Median) |
---|---|
Placebo | 11.5 |
Antifungal | 13 |
Measure of the duration of the participant's hospital stay (NCT00934934)
Timeframe: 90 days
Intervention | days (Median) |
---|---|
Placebo | 29 |
Antifungal | 28 |
Number of days free of ICU (NCT00934934)
Timeframe: 28 days
Intervention | days (Median) |
---|---|
Placebo | 14 |
Antifungal | 4 |
(NCT00934934)
Timeframe: 28 days
Intervention | pg/ml (Mean) |
---|---|
VAP withCandida | 97.5 |
VAP Without Candida | 3 |
Overall recruitment rate per site (NCT00934934)
Timeframe: 32 months
Intervention | participants per site /month (Number) |
---|---|
Overall | 0.6 |
(NCT00934934)
Timeframe: 28 days
Intervention | ng/ml (Mean) |
---|---|
VAP withCandida | 3.0 |
VAP Without Candida | 22.5 |
Number of days in ICU free of ventilation (NCT00934934)
Timeframe: 28 days
Intervention | days (Median) |
---|---|
Placebo | 8 |
Antifungal | 9 |
1 review available for fluconazole and Ventilator-Associated Pneumonia
Article | Year |
---|---|
Prevention of nosocomial infections in neonatal intensive care units.
Topics: Anti-Infective Agents; Central Venous Catheters; Contraindications; Cross Infection; Fluconazole; Hi | 2013 |
1 other study available for fluconazole and Ventilator-Associated Pneumonia
Article | Year |
---|---|
Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study.
Topics: Antifungal Agents; Bronchi; Candida; Case-Control Studies; Female; Fluconazole; Humans; Male; Middle | 2007 |